More than $50 million in fines has been issued to drug giant Sanofi by France’s Antitrust Authority for what the regulator called a ‘smear campaign’ by the pharmaceutical company against generics drugs. Reports say the Authority found that Sanofi hampered competition by encouraging doctors and pharmacies to provide its brand name blood thinner drug Plavix instead of the generic form. Sanofi said it will appeal the fine. According to reports, Sanofi has looked to up profits since patent protection ended for two of its top-earning drugs, Plavix and blook pressure drug Avapro.
Featured News
DOJ Prosecutors Advise Against Criminal Charges in Live Nation Antitrust Probe
Dec 17, 2025 by
CPI
Supreme Court Closes Door on REX Antitrust Case Against Realtors Group
Dec 17, 2025 by
CPI
PepsiCo and Walmart Face Federal Lawsuit Alleging Long-Running Price-Fixing Scheme
Dec 17, 2025 by
CPI
Utah Reaches Antitrust Settlement With Sandoz Over Generic Drug Pricing
Dec 17, 2025 by
CPI
China Regulator Flags ‘Lowest-Price’ Demands as Potential Antitrust Violations
Dec 17, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – CRESSE Insights
Dec 16, 2025 by
CPI
Learning from Divergence: The Role of Cross-Country Comparisons in the Evaluation of the DMA
Dec 16, 2025 by
Federico Bruni
New Regulatory Tools for the EU Foreign Direct Investment Screening and Foreign Subsidies Regulation
Dec 16, 2025 by
Ioannis Kokkoris
“Suite Dreams”: Market Definition and Complementarity in the Digital Age
Dec 16, 2025 by
Romain Bizet & Matteo Foschi
The Interaction Between Competition Policy and Consumer Protection: Institutional Design, Behavioral Insights, and Emerging Challenges in Digital Markets
Dec 16, 2025 by
Alessandra Tonazzi